Amryt Pharma (Amryt Pharma) EPS (Diluted) : $-0.30 (TTM As of Sep. 2022)

View and export this data going back to 2019. Start your Free Trial

What is Amryt Pharma EPS (Diluted)?

Amryt Pharma's Earnings per Share (Diluted) for the three months ended in Sep. 2022 was $-0.30. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 was $-0.30.

Amryt Pharma's EPS (Basic) for the three months ended in Sep. 2022 was $-0.30. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2022 was $-0.30.

Amryt Pharma's EPS without NRI for the three months ended in Sep. 2022 was $-0.30. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2022 was $-0.30.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 12 years, Amryt Pharma's highest 3-Year average EPS without NRI Growth Rate was 7.90% per year. The lowest was -164.00% per year. And the median was -71.15% per year.

Amryt Pharma EPS (Diluted) Historical Data

The historical data trend for Amryt Pharma's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amryt Pharma EPS (Diluted) Chart

Amryt Pharma Annual Data

Trend

Mar12

Mar13

Mar14

Mar15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

EPS (Diluted)

Get a 7-Day Free Trial

-4.22

-3.33

-4.15

-3.30

0.02

Amryt Pharma Quarterly Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
EPS (Diluted)	Get a 7-Day Free Trial															-0.35	0.35	-0.25	-0.10	-0.30

Competitive Comparison of Amryt Pharma's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Amryt Pharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amryt Pharma's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amryt Pharma's PE Ratio distribution charts can be found below:

* The bar in red indicates where Amryt Pharma's PE Ratio falls into.

Amryt Pharma EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Amryt Pharma's Diluted EPS for the fiscal year that ended in Dec. 2021 is calculated as

Diluted EPS (A: Dec. 2021 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(1	-	0)	/	49.396
	=	0.02

Amryt Pharma's Diluted EPS for the quarter that ended in Sep. 2022 is calculated as

Diluted EPS (Q: Sep. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-20.795	-	0)	/	64.046
	=	-0.32

EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.30

Amryt Pharma (NAS:AMYT) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Amryt Pharma EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Amryt Pharma's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Amryt Pharma (Amryt Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amryt Pharma PLC (NAS:AMYT) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

196 High Road, Dept 920A, Wood Green, London, GBR, N22 8HH

Website

http://www.amrytpharma.com

Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).